Scholarlink

Objective <p>To evaluate the efficacy of MWA for patients aged ≥ 75 years with stage I NSCLC, and to explore the impacts of age and comorbidities on the long-term outcomes.</p> Methods <p>Patients with stage I NSCLC underwent MWA between November 2016 and December 2020 were retrospectively enrolled. Patients were stratified into two cohorts: ≥ 75 years and &lt; 75 years. Propensity score matching was implemented to control selection bias. Primary endpoints included overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS). Secondary endpoints included independent risk factors influencing OS.</p> Results <p>138 patients were successfully matched, with 69 in each group. The 1-, 3-, and 5-year OS were 95.7%, 82.6%, and 72.8% in patients aged ≥ 75 years, while 97.1%, 89.9%, and 80.3% in younger patients. There was no significant difference (<i>p</i> = 0.212). The 1-, 3-, and 5-year CSS were 100.0% vs. 98.6%, 92.2% vs. 92.6%, and 83.6% vs. 89.2%, respectively. No significant difference was observed (<i>p</i> = 0.661). The 1-, 3-, and 5-year RFS were 82.1% vs. 88.4%, 60.6% vs. 63.3%, and 58.9% vs. 61.6% without significant difference (<i>p</i> = 0.537). The multivariate COX analysis showed age and Charlson comorbidity index (CCI) were not prognostic factors. Idiopathic pulmonary fibrosis (IPF)/chronic obstructive pulmonary disease (COPD) was an independent risk factor (95% CI 1.32–8.24; <i>p</i> = 0.011).</p> Conclusion <p>MWA is an efficacious tool for patients aged ≥ 75 years with NSCLC. There are no significant differences in efficacy compared with younger patients. Age and CCI are not significant factors associated with prognosis, while IPF/COPD is an independent risk factor.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of CT-guided microwave ablation for stage I non-small cell lung cancer in elderly patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月15日

查看全文
  • JinZhao Peng,
  • Jing Luo,
  • Ling Yang,
  • ZhiXin Bie,
  • YuanMing Li,
  • DongDong Wang,
  • XiaoGuang Li

摘要

Objective

To evaluate the efficacy of MWA for patients aged ≥ 75 years with stage I NSCLC, and to explore the impacts of age and comorbidities on the long-term outcomes.

Methods

Patients with stage I NSCLC underwent MWA between November 2016 and December 2020 were retrospectively enrolled. Patients were stratified into two cohorts: ≥ 75 years and < 75 years. Propensity score matching was implemented to control selection bias. Primary endpoints included overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS). Secondary endpoints included independent risk factors influencing OS.

Results

138 patients were successfully matched, with 69 in each group. The 1-, 3-, and 5-year OS were 95.7%, 82.6%, and 72.8% in patients aged ≥ 75 years, while 97.1%, 89.9%, and 80.3% in younger patients. There was no significant difference (p = 0.212). The 1-, 3-, and 5-year CSS were 100.0% vs. 98.6%, 92.2% vs. 92.6%, and 83.6% vs. 89.2%, respectively. No significant difference was observed (p = 0.661). The 1-, 3-, and 5-year RFS were 82.1% vs. 88.4%, 60.6% vs. 63.3%, and 58.9% vs. 61.6% without significant difference (p = 0.537). The multivariate COX analysis showed age and Charlson comorbidity index (CCI) were not prognostic factors. Idiopathic pulmonary fibrosis (IPF)/chronic obstructive pulmonary disease (COPD) was an independent risk factor (95% CI 1.32–8.24; p = 0.011).

Conclusion

MWA is an efficacious tool for patients aged ≥ 75 years with NSCLC. There are no significant differences in efficacy compared with younger patients. Age and CCI are not significant factors associated with prognosis, while IPF/COPD is an independent risk factor.